SCHEMBL7653397

SCHEMBL7653397

CC(CNS(=O)(=O)C(C)C)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 11/20 0.56
EPHX1 P07099 1/20 0.43
MMP13 P45452 3/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
EED O75530 1/20 0.43
RBBP4 Q09028 1/20 0.43
SUZ12 Q15022 1/20 0.43
EZH2 Q15910 1/20 0.43
AEBP2 Q6ZN18 1/20 0.43
DPP4 P27487 1/20 0.42
STS P08842 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22445488 0.84 GPR119 (0.53) GPR119EPHX1STS
SCHEMBL22441470 0.84 GPR119 (0.53) GPR119EPHX1STS
SCHEMBL6402117 0.82 TGFBR1 (0.53) GPR119MAPT
SCHEMBL25819368 0.80 GPR119 (0.56) GPR119EPHX1NPC1ALDH1A1MAPT
SCHEMBL25819386 0.80 GPR119 (0.56) GPR119EPHX1NPC1ALDH1A1MAPT
SCHEMBL13600068 0.80 GPR119 (0.56) GPR119EPHX1NPC1ALDH1A1MAPT
SCHEMBL25033887 0.78 GPR119 (0.55) GPR119EPHX1NPC1ALDH1A1MAPT
SCHEMBL119948 0.78 GPR119 (0.55) GPR119EPHX1NPC1ALDH1A1MAPT
SCHEMBL7495690 0.78 GPR119 (0.55) GPR119EPHX1NPC1ALDH1A1MAPT
SCHEMBL22445587 0.77 GPR119 (0.54) GPR119EPHX1NPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355655-B1 TREATING A COGNITIVE DISORDER, A NEURO-DEGENERATIVE DISORDER; AGE-RELATED DEMENTIA; AGE-INDUCED MEMORY IMPAIRMENT; A MOVEMENT DISORDER, ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER; PSYCHOSIS; COGNITIVE DEFICITS ELI LILLY AND COMPANY 2002-03-12 US disclosed
EP-1100498-A4 HETEROCYCLIC SULPHONAMIDE DERIVATIVES LILLY CO ELI (US) 2001-10-24 EP disclosed
EP-1100498-A1 HETEROCYCLIC SULPHONAMIDE DERIVATIVES Eli Lilly & Company (US) 2001-05-23 EP disclosed
WO-2000006159-A1 HETEROCYCLIC SULPHONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed